Hypothesis

Accumulated mitochondrial DNA (mtDNA) mutations promote vascular aging not only by impairing oxidative phosphorylation but also by releasing mtDNA fragments into the cytosol, where they activate the cGAS-STING innate immune pathway. This triggers a chronic type‑I interferon response and endothelial senescence that sustains oxidative stress and nitric oxide (NO) deficiency, creating a feed‑forward loop that accelerates arterial stiffening. Consequently, therapeutic inhibition of cGAS‑STING signaling should improve vascular function in aged organisms even when mtDNA heteroplasmy remains unchanged.

Mechanistic Rationale

• mtDNA lacks protective histones and replicates near the electron transport chain, making it prone to oxidative damage [1]. When mitochondria become permeabilized—due to ROS‑induced permeability transition pore opening or mitophagy failure—double‑stranded mtDNA escapes into the cytosol.
• Cytosolic mtDNA is a potent ligand for the cyclic GMP‑AMP synthase (cGAS) enzyme, which produces 2′‑3′‑cGAMP and activates STING, leading to IRF3 phosphorylation and type‑I IFN‑β production [2].
• Persistent type‑I IFN signaling drives a senescence‑associated secretory phenotype (SASP) in endothelial cells, characterized by IL‑6, IL‑1β, and TNF‑α secretion, which further uncouples eNOS and shifts its output from NO to superoxide [3].
• Superoxide scavenges NO, forming peroxynitrite and reducing NO bioavailability, thereby exacerbating endothelial dysfunction and promoting arterial stiffness [4].
• Importantly, this cascade can operate independently of the actual load of pathogenic mtDNA mutations; the key trigger is the presence of immunogenic mtDNA in the cytosol.

Testable Predictions

1. Inhibition of cGAS‑STING in aged mice will restore endothelial NO production and reduce arterial pulse wave velocity without significantly altering mtDNA heteroplasmy levels.
2. Elevated cytosolic mtDNA will be detectable in aortic endothelium of old mice and will correlate with STING activation markers (p‑TBK1, p‑IRF3) and SASP factors.
3. Genetic ablation of STING specifically in endothelial cells will recapitulate the protective effects of pharmacologic inhibition, confirming cell‑type specificity.
4. Exogenous transfection of purified mtDNA into young endothelial cultures will induce STING activation, eNOS uncoupling, and superoxide production, replicating aspects of the aged phenotype.

Experimental Approach

• Animal model: Use 24‑month‑old C57BL/6 mice. Treat one cohort with a selective cGAS inhibitor (e.g., RU.521) or STING antagonist (e.g., H‑151) for 8 weeks; control cohort receives vehicle.
• Endpoints: Measure aortic mtDNA heteroplasmy by duplex sequencing, cytosolic mtDNA by qPCR of cytosolic fractions, STING pathway activation by Western blot (p‑TBK1, p‑IRF3), SASP cytokines by ELISA, NO bioavailability via DAF‑FM fluorescence, and arterial stiffness via pulse wave velocity.
• Cellular validation: Isolate primary aortic endothelial cells from young and old mice; assess STING activation after mtDNA transfection and rescue with cGAS/STING knockdown.
• Rescue experiment: Administer mitochondrially‑targeted antioxidant (MitoQ) alongside cGAS‑STING inhibition to determine whether ROS reduction adds benefit beyond immune pathway blockade.

Potential Outcomes

• If cGAS‑STING inhibition improves NO signaling and arterial stiffness while mtDNA heteroplasmy remains high, the hypothesis is supported, indicating that mtDNA‑driven innate immunity is a pivotal effector of vascular aging.
• If vascular parameters improve only when mtDNA load is reduced, the hypothesis is refuted, suggesting that mutagenic burden, not immune signaling, is the dominant factor.
• If neither intervention yields benefit, alternative mechanisms (e.g., mitochondrial‑derived peptides or metabolic reprogramming) must be considered.

Implications

This work would reposition mtDNA from a passive genetic substrate to an active danger signal that orchestrates vascular aging through innate immune activation. It would justify developing cGAS‑STING modulators as senolytics or anti‑inflammatory agents for age‑related cardiovascular disease, complementing existing strategies that target mitochondrial biogenesis or ROS scavenging.